Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT01527591
NA
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
Sponsor: University of California, Los Angeles
View on ClinicalTrials.gov
Summary
The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
Official title: Safety And Long-Term Immunogenicity Of The 13-Valent Pneumococcal Conjugate Vaccine In Children Who Are Solid Organ Transplant Recipients
Key Details
Gender
All
Age Range
12 Months - 59 Months
Study Type
INTERVENTIONAL
Enrollment
17
Start Date
2012-02-01
Completion Date
2025-12-30
Last Updated
2025-04-02
Healthy Volunteers
No
Interventions
BIOLOGICAL
Pneumococcal Conjugate Vaccine 13 (PCV13)
A single intramuscular dose of 0.5 mL.
Locations (1)
UCLA
Los Angeles, California, United States